Pseudomonas aeruginosa associated with severity of non-cystic fibrosis bronchiectasis measured by the modified bronchiectasis severity score (BSI) and the FACED: The US bronchiectasis and NTM Research Registry (BRR) study. (February 2021)

• Record Type: Journal Article
• Authors: Choate, Radmila; Aksamit, Timothy R.; Mannino, David; Addrizzo-Harris, Doreen; Barker, Alan; Basavaraj, Ashwin; Daley, Charles L.; Daniels, M. Leigh Anne; Eden, Edward; DiMango, Angela; Fennelly, Kevin; Griffith, David E.; Johnson, Margaret M.; Knowles, Michael R.; McShane, Pamela J.; Metersky, Mark L.; Noone, Peadar G.; O'Donnell, Anne E.; Olivier, Kenneth N.; Salathe, Matthias A.; Schmid, Andreas; Thomashow, Byron; Tino, Gregory; Winthrop, Kevin L.; Stone, Glenda
• Is Part Of: Respiratory medicine. Volume 177(2021)
• Publication Date: 2021-02
• Subjects: Non-cystic fibrosis bronchiectasis -- Pseudomonas aeruginosa -- Bronchiectasis severity -- Severity scores -- Registry; NCFB Non-cystic fibrosis bronchiectasis -- NTM Nontuberculous mycobacteria -- BRR Bronchiectasis and NTM Research Registry -- NTMLD NTM lung disease -- PA Pseudomonas aeruginosa -- BSI Bronchiectasis Severity Index -- FEV1 forced expiratory volume in 1 s -- FVC forced vital capacity; Chest -- Diseases -- Periodicals; Chest -- Diseases -- Great Britain -- Periodicals; Respiratory organs -- Diseases -- Periodicals; Respiratory Tract Diseases -- Periodicals; Appareil respiratoire -- Maladies -- Périodiques; Thorax -- Maladies -- Périodiques; Appareil respiratoire -- Maladies -- Traitement -- Périodiques; Electronic journals; 616.2
• DOI: 10.1016/j.rmed.2020.106285
• Languages: English
• ISSNs: 0954-6111

Abstract

Abstract: Rationale: Non-cystic fibrosis bronchiectasis (NCFB) is characterized by dilated bronchi, poor mucus clearance and susceptibility to bacterial infection. Pseudomonas aeruginosa (PA) is one of the most frequently isolated pathogens in patients with NCFB. The purpose of this study was to evaluate the association between presence of PA and disease severity in patients within the US Bronchiectasis and Nontuberculous mycobacteria (NTM) Research Registry (BRR). Methods: Baseline US BRR data from adult patients with NCFB collected between 2008 and 2018 was used for this study. The presence of PA was defined as one or more positive PA cultures within two years prior to enrollment. Modified Bronchiectasis Severity Index (m-BSI) and modified FACED (m-FACED) were computed to evaluate severity of bronchiectasis. Unadjusted and multivariable multinomial regression models were used to assess the association between presence of PA and severity of bronchiectasis. Results: Average age of the study participants (n = 1831) was 63.7 years (SD = 14.1), 91.5% white, and 78.8% female. Presence of PA was identified in 25.4% of the patients. Patients with presence of PA had significantly lower mean pre-bronchodilator FEV1% predicted compared to those without PA (62.8% vs. 73.7%, p < .0001). In multivariate analyses, patients with presence of PA had significantly greater odds for having high (ORadj = 6.15 (95%CI:3.98–9.50) and intermediate (ORadj = 2.06 (95%CI:1.37–3.09) severity vs. low severity on m-BSI. Conclusion: The presence of PA is common in patients with NCFB within the Bronchiectasis and NTM Research Registry. Severity of bronchiectasis is significantly greater in patients with PA which emphasizes high burden of the disease. Highlights: Prevalence of Pseudomonas aeruginosa is high in patients within the US BRR. Modified bronchiectasis severity indices were used to estimate disease burden. Severity of bronchiectasis is significantly greater in patients with Pseudomonas. Higher disease severity remained after excluding Pseudomonas variable from indices.